Tanvi Harishbhai Patel

Assistant Professor and hospitalist in the Division of Hematology/Oncology, Multiple Myeloma Section

UAMS

Also affiliated: University of Arkansas Medical Center (2022)

4 h-index 13 pubs 58 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Tanvi Harishbhai Patel's research focuses on hematologic malignancies, particularly multiple myeloma. Her work investigates novel therapeutic approaches and treatment outcomes for this patient population. Recent publications include studies on the use of autologous stem cell boosts to manage hematotoxicity following CAR T-cell therapy and the role of cereblon E3 ligase modulators like mezigdomide and iberdomide in treating multiple myeloma. She has also examined the psychological impact of precursor conditions such as monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Patel's research extends to prognostic factors, as evidenced by her work on an immune prognostic score predicting infection risk and survival in relapsed multiple myeloma patients treated with bispecific antibodies. Her scholarly contributions also include a review on HER2 as a biomarker in various cancers and a case report on acute disseminated encephalomyelitis.

Metrics

h-index: 4
Publications: 13
Citations: 58

Positions

Assistant Professor and hospitalist in the Division of Hematology/Oncology, Multiple Myeloma Section publications 2021–2024

University of Arkansas for Medical Sciences Institution web page

Selected Publications

Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 1 citation DOI OpenAlex
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)

Blood DOI OpenAlex
Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM) (2024)

Blood 2 citations DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)

Clinical Hematology International 13 citations DOI OpenAlex
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies (2024)

British Journal of Haematology 3 citations DOI OpenAlex
Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma (2024)

Clinical Lymphoma Myeloma & Leukemia 14 citations DOI OpenAlex
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. (2024)

Journal of Clinical Oncology 2 citations DOI OpenAlex
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024)

Bone Marrow Transplantation 27 citations DOI OpenAlex
A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma (2024)

Transplantation and Cellular Therapy 1 citation DOI OpenAlex
Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm (2024)

Cureus DOI OpenAlex
The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T in Multiple Myeloma (2023)

Blood 1 citation DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2023)

Blood DOI OpenAlex
Necrotizing Enterocolitis in a Patient With Newly Diagnosed Multiple Myeloma and Hyperviscosity Syndrome: A Case Report (2023)

Cureus 1 citation DOI OpenAlex
Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature (2023)

Cureus 2 citations DOI OpenAlex
A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers (2023)

Onco 12 citations DOI OpenAlex